Kinetics of immunological parameters in patients with malignant melanoma treated with hyperthermic isolated limb perfusion-Reference-Cited by-同舟云学术

Kinetics of immunological parameters in patients with malignant melanoma treated with hyperthermic isolated limb perfusion

Published:1997-05 Issue:1 Volume:15 Page:1-8
ISSN:0923-1811
Container-title:Journal of Dermatological Science
language:en
Short-container-title:Journal of Dermatological Science

Author:

Nakayama Juichiro,Nakao Tomoko,Mashino Toshihiko,Nagae Shonosuke,Hori Yoshiaki,Mayumi Hisanori,Tominaga Ryuji,Yasui Hisataka,Matsuda Kazuhisa,Takahashi Shosuke

Publisher

Elsevier BV

Subject

Dermatology,Molecular Biology,Biochemistry

Reference12 articles.

1. The role of regional hyperthermic cytostatic perfusion in the treatment of extremity melanoma;Ghussen;Cancer,1988

2. Hyperthermic isolated perfusion with melphalan in the treatment of advanced malignant melanoma in the lower limb;Skene;Br J Surg,1990

3. Two cases of metastatic malignant melanoma of the lower limb treated with hyperthermic isolated limb perfusion with concomitant infusion of either carboplatin or β-interferon;Nakayama;J Dermatol (Tokyo),1996

4. The role of surgery in cutaneous malignant melanoma;Coit,1993

5. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma;Lienard;J Clin Oncol,1992

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Animal (mouse) models of melanoma;Animal Models in Cancer Drug Discovery;2019

2. Therapeutic use of anti-CTLA-4 antibodies;International Immunology;2014-07-18

3. Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma;Annals of Surgical Oncology;2014-04-04

4. Isolated limb infusion as a model to test new agents to treat metastatic melanoma;Journal of Surgical Oncology;2013-11-20

5. Glutathione-Redox Balance Regulates c-rel–Driven IL-12 Production in Macrophages: Possible Implications in Antituberculosis Immunotherapy;The Journal of Immunology;2010-02-17